Cardio Talk Latest Research

With Isabelle van Gelder, Michiel Rienstra and Michelle Lobeek, University Medical Centre Groningen - The Netherlands, and Prash Sanders, University of Adelaide - Australia. In this episode of Cardio Talk Latest Research, Isabelle van Gelder interviews Michiel Rienstra, Michelle Lobeek and Prash Sanders about the EHRA-PATHS clinical trial, which focuses on improving the quality of life for patients with atrial fibrillation and comorbidities. They discuss the clinical trial's design, methodology, and implementation in detail. This podcast was recorded in April 2024. 

With Machteld Boonstra, Amsterdam University Medical Centre - The Netherlands, and Iker Garcia, HiTZ Basque Center for Language Technologies - Spain.  In this episode of Cardio Talk Latest Research, Machteld Boonstra interviews Iker Garcia about multilingual large language models and their benefits. They discuss the limitations of these models in various languages, how to make them accessible to everyone, and the process of acquiring data to train these models. This podcast was recorded in February 2024.

With Kalliopi Keramida, Agios Savvas General Oncology Hospital, Athens -  Greece, and Dorothea Tsekoura, National and Kapodistrian University of Athens Medical School, Athens - Greece. In this episode of Cardio Talk Latest Research, Kalliopi Keramida and Dorothea Tsekoura discuss cardiotoxicity in elderly breast cancer patients. They note that breast cancer is now the most common form of cancer worldwide, with a strong correlation to aging. They explore studies focused on assessing cardiotoxicity in elderly patients with breast cancer. This podcast was recorded in October 2023.

With Alan Fraser, University Hospital of Wales, Cardiff - UK and Anne Lubbeke Wolff, University of Oxford - UK. In this episode of Cardio Talk Latest Research, Alan Fraser interviews Anne Lubbeke Wolff about the evidence supporting medical devices in Europe and the valuable lessons we can learn from the field of orthopedics. They explore the challenges surrounding transparency in device evaluation, the scarcity of literature on the pre-market phase, and the limitations of the post-market phase.